Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
about
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomicCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewKirsten Ras* oncogene: Significance of its discovery in human cancer researchBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASCorrelation of human epidermal growth factor receptor protein expression and colorectal cancerCancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapiesCan K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic reviewTargeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategyMolecular Technologies in the Clinical Diagnostic LaboratoryThe next steps in next-gen sequencing of cancer genomesScience gone translational: the OX40 agonist storyDasatinib sensitizes KRAS mutant colorectal tumors to cetuximabGene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceThe possibility of clinical sequencing in the management of cancerPharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsKRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessmentHuman variation databasesSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKEvolving Therapies and FAK Inhibitors for the Treatment of CancerMultiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastomaDoes KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technologyExpression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancerThe prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.Gene profiling of MTA1 identifies novel gene targets and functions.[WHO classification 2010 for the lower gastrointestinal tract: what is new?].mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers.HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerAXL mediates resistance to cetuximab therapyPhospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells.Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatographyAntitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutationsPrognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic diseaseComputational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
P2860
Q21128654-B3032CCC-6798-4AEF-9F72-5E276E636411Q26740067-7A1F4B7A-7249-4096-85B6-3EF662AC4AB2Q26751212-0BBE427E-1D28-429F-8D64-240523983F26Q26766535-EE2E44E6-28CF-4126-87B8-7B7896CCD425Q26801167-3552BE32-EC72-4EF8-951E-EB9BB351124BQ26823118-C795E1D4-5DC3-4A2F-AAFF-62BCA882C163Q26863194-745101B4-3CE3-405E-9FF0-3365B27CAF14Q26863340-35CA299F-91FA-4924-9CE0-7EBFEA289A42Q26996463-D2648DDF-34C1-401A-B390-0BEFA16A1F72Q26998894-7A9C5E84-87B1-443B-869E-9A0EEC7EFF56Q27022436-D9B89B85-3BDB-4ADE-80C4-20C9578C7B52Q27851586-245F5D6B-943F-4BC6-9062-1E52DD55676FQ27853108-F0D54499-2E4A-474A-A30B-1FDDFBB17B5DQ28071772-C49163C9-46E9-496C-ACD8-D9CCC31C3E86Q28072144-296F4010-025A-47BA-98AB-5B2A70D54322Q28382921-35026588-00DF-4B97-A04C-5680DF2368CFQ28478344-4843B30A-AD3F-4CCC-809F-5E46E82C0D9CQ28741021-2BE252A6-8606-4804-9A3F-B76117D29D76Q28750141-41BD4814-C1A1-4477-AC9B-8517105FC999Q28833740-278398CC-8AA9-46CA-8361-4B9C00869304Q28972291-49F03329-3FA2-48AD-A73E-E0A51E3CBE05Q30405446-D6BCD895-BE99-4C93-9832-8C4ED65D6630Q33553166-80A4F6FE-3775-4774-9D17-F84220B811CDQ33587972-FB8E38EB-1B1B-446C-B2CB-D33DFC7CFA5CQ33611056-1B245430-CBFA-45CC-A982-1E19328AC86BQ33631430-111F0EC0-4AC3-4020-8657-56A5333FBCE5Q33679614-DE139DC3-56D3-4216-B9C4-319126D8D2AAQ33778129-8F39D05E-B45E-4348-9F4A-70E0F6633ECDQ33833747-1018D75A-BB9C-47DE-ADEF-D9C2B11F71B3Q34019220-30CE2501-5AFD-49E6-8EE8-BFA5FA1350D0Q34049613-266A6148-EE7D-42BE-817D-6A8007D7C20BQ34052270-05CFA829-D148-4875-A796-72715F0367FAQ34173413-5B65CE99-9831-4F98-BFCB-68E882689E70Q34204829-4EB3D2BD-2910-4F1F-AB1D-34FB944B88B5Q34218363-14720945-E589-47F7-8953-C1068C23C148Q34239695-6E47016D-C0A2-44E8-A10F-5E65A66BA832Q34387843-7100B289-38EB-4278-BDB6-A4B96C7565E4Q34470974-D4449265-E9E0-40ED-B71C-2220E4A0E2B0Q34598203-D989E83D-BD7E-4A9F-A8E7-4AE06AFCDCC5Q34622865-288B4FD5-1001-4115-B49F-DD905E931A86
P2860
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@en
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@nl
type
label
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@en
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@nl
prefLabel
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@en
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
@nl
P50
P1476
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
@en
P2093
Eric Van Cutsem
Sabine Tejpar
P304
P356
10.1038/NRCLINONC.2009.111
P407
P577
2009-07-28T00:00:00Z